$151 Million is the total value of Aisling Capital Management LP's 17 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 10.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BBIO | BridgeBio Pharma Inc. (BBIO) | $60,317,000 | +9.5% | 6,068,125 | 0.0% | 40.05% | +1.9% | |
| SNDX | Syndax Pharmaceuticals, Inc. (SNDX) | $24,631,000 | +24.9% | 1,025,000 | 0.0% | 16.36% | +16.2% | |
| VRNA | Verona Pharma plc (VRNA)sponsored ads | $13,618,000 | +143.9% | 1,332,485 | 0.0% | 9.04% | +127.0% | |
| GLUE | Monte Rosa Therapeutics Inc. (GLUE) | $12,029,000 | -15.5% | 1,472,331 | 0.0% | 7.99% | -21.4% | |
| ACRS | Aclaris Theraputics Inc. (ACRS) | $9,986,000 | +12.7% | 634,455 | 0.0% | 6.63% | +4.9% | |
| BMEA | Biomea Fusion Inc. (BMEA) | $7,812,000 | -18.4% | 798,757 | 0.0% | 5.19% | -24.0% | |
| NUVB | Nuvation Bio Inc. (NUVB) | $5,692,000 | -30.9% | 2,541,009 | 0.0% | 3.78% | -35.6% | |
| PSTX | Poseida Therapeutics Inc. (PSTX) | $3,683,000 | +36.8% | 1,043,267 | 0.0% | 2.45% | +27.3% | |
| ELEV | Elevation Oncology Inc. (ELEV) | $3,203,000 | -19.3% | 2,834,910 | 0.0% | 2.13% | -24.9% | |
| RPHM | Reneo Pharmaceuticals Inc. (RPHM) | $2,968,000 | +26.4% | 886,075 | 0.0% | 1.97% | +17.7% | |
| SPRB | Spruce Biosciences, Inc. (SPRB) | $1,652,000 | -21.3% | 1,205,511 | 0.0% | 1.10% | -26.7% | |
| VIRX | Viracta Therapeutics Inc. (VIRX) | $1,232,000 | +10.0% | 288,571 | 0.0% | 0.82% | +2.4% | |
| MRKR | Marker Therapeutics, Inc. (MRKR) | $1,163,000 | +12.2% | 3,142,857 | 0.0% | 0.77% | +4.3% | |
| AGLE | Aeglea Biotherapeutics Inc. (AGLE) | $890,000 | +4.2% | 1,691,151 | 0.0% | 0.59% | -3.0% | |
| AVRO | AVROBIO, Inc. (AVRO) | $646,000 | -30.5% | 1,009,779 | 0.0% | 0.43% | -35.3% | |
| BCEL | Atreca Inc. (BCEL) | $609,000 | -12.2% | 387,653 | 0.0% | 0.40% | -18.4% | |
| TALS | Sell | Talaris Therapeutics Inc. (TALS) | $460,000 | -85.1% | 175,000 | -74.4% | 0.30% | -86.1% |
| Exit | Nabriva Therapeutics plc (NBRV) | $0 | – | -90,000 | -100.0% | -0.01% | – | |
| ZSAN | Exit | Zosano Pharma Corporation (ZSAN) | $0 | – | -77,663 | -100.0% | -0.02% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-11-03
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Verona Pharma plc (VRNA) | 20 | Q3 2023 | 23.0% |
| AVROBIO, Inc. (AVRO) | 20 | Q3 2023 | 13.6% |
| Aclaris Theraputics Inc. (ACRS) | 20 | Q3 2023 | 6.6% |
| Aeglea Biotherapeutics Inc. (AGLE) | 19 | Q2 2023 | 7.5% |
| BridgeBio Pharma Inc. (BBIO) | 18 | Q3 2023 | 67.3% |
| Marker Therapeutics, Inc. (MRKR) | 18 | Q1 2023 | 11.7% |
| Atreca Inc. (BCEL) | 18 | Q3 2023 | 3.1% |
| Syndax Pharmaceuticals, Inc. (SNDX) | 15 | Q3 2023 | 17.2% |
| Zosano Pharma Corporation (ZSAN) | 15 | Q2 2022 | 5.8% |
| ObsEva SA (OBSV) | 14 | Q1 2022 | 18.5% |
View Aisling Capital Management LP's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-07 |
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-09 |
| 13F-HR | 2023-02-09 |
| 13F-HR | 2022-11-03 |
| 13F-HR | 2022-08-10 |
| 13F-HR | 2022-05-10 |
| 13F-HR | 2022-02-18 |
| 13F-HR | 2021-11-12 |
View Aisling Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.